| Literature DB >> 29379794 |
Eduardo Esteves1, Nuno Rosa1, Maria José Correia1, Joel P Arrais2, Marlene Barros1.
Abstract
Identifying ZIKV factors interfering with human host pathways represents a major challenge in understanding ZIKV tropism and pathogenesis. The integration of proteomic, gene expression and Protein-Protein Interactions (PPIs) established between ZIKV and human host proteins predicted by the OralInt algorithm identified 1898 interactions with medium or high score (≥0.7). Targets implicated in vesicular traffic and docking were identified. New receptors involved in endocytosis pathways as ZIKV entry targets, using both clathrin-dependent (17 receptors) and independent (10 receptors) pathways, are described. New targets used by the ZIKV to undermine the host's antiviral immune response are proposed based on predicted interactions established between the virus and host cell receptors and/or proteins with an effector or signaling role in the immune response such as IFN receptors and TLR. Complement and cytokines are proposed as extracellular potential interacting partners of the secreted form of NS1 ZIKV protein. Altogether, in this article, 18 new human targets for structural and nonstructural ZIKV proteins are proposed. These results are of great relevance for the understanding of viral pathogenesis and consequently the development of preventive (vaccines) and therapeutic targets for ZIKV infection management.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29379794 PMCID: PMC5742907 DOI: 10.1155/2017/1734151
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Number of interactions between human and ZIKV proteins predicted by OralInt according the score (0.9–1: very high confidence; 0.7–0.9: high confidence; 0.7–0.4: medium confidence). Quantification refers to the number of human proteins which have been identified as being expressed upon ZIKV infection of fibroblast (skin) and human cortical neuronal progenitor cells (hNPCs).
|
| OralInt score 0.9–1 | OralInt score 0.7–0.9 | OralInt score 0.4–0.7 | |||
|---|---|---|---|---|---|---|
| PPI | Quantified hNPCs | PPI | Quantified hNPCs | PPI | Quantified hNPCs | |
| Capsid (C) | - | - | 168 | 64 | 3236 | 1055 + 14 (4) |
| Envelope (E) | 7 | 3 | 124 | 42 + 1 | 2757 | 838 + 11 (3) |
| Membrane (M) | 1 | - | 67 | 15 | 1314 | 369 + 3 |
| NS1 | 3 | - | 119 | 39 + 1 | 2612 | 824 + 10 (3) |
| NS2A | 2 | 1 | 264 | 81 + 1 | 4478 | 1486 + 17 (6) |
| NS2B | 11 | 7 | 439 | 148 + 2 | 4649 | 1604 + 18 (4) |
| NS3 | 1 | 1 | 33 | 12 + 1 | 979 | 304 + 3 (1) |
| NS4A | - | - | 124 | 41 + 1 | 2618 | 840 + 12 (3) |
| NS4B | 9 | - | 292 | 83 + 1 | 3858 | 1189 + 12 (4) |
| NS5 | 5 | 2 | 229 | 78 + 1 | 3970 | 1330 + 17 (5) |
|
| ||||||
|
|
|
|
|
|
|
|
[56]; [17].
Number of human proteins establishing PPIs exclusively with each ZIKV protein; human proteins expression regulation upon ZIKV infection (when available) and respective presence in saliva. Only PPIs with scores ≥ 0.4 are shown.
|
| Total PPIs | Human proteins with expression data | Proteins present in saliva | |
|---|---|---|---|---|
| Upregulated | Downregulated | |||
| E | 105 | 16 | 21 | 8 |
| M | 62 | 8 | 9 | 3 |
| NS1 | 131 | 16 | 14 | 4 |
| NS2A | 638 | 85 | 94 | 22 |
| NS2B | 1066 | 214 | 175 | 45 |
| NS3 | 1 | - | 1 | - |
| NS4A | 46 | 5 | 7 | 3 |
| NS4B | 300 | 37 | 43 | 8 |
| NS5 | 557 | 90 | 106 | 22 |
Quantification in human cortical neural progenitor cells (hNPCs) [56] and skin (fibroblasts) [17]. Presence in saliva from OralCard [57, 58].
Figure 1Network of OralInt predicted PPIs (score ≥ 0.9) established between ZIKV proteins (blue) and human proteins (orange). The size of the node denotes the degree (number of interactions established). Red denotes underexpressed and green overexpressed proteins. Expression data from Tang et al. 2016 [56]. Diagram generated with Cytoscape V3.5.0 [59].
Membrane receptors as potential targets for ZIKV entry into host cells. Only proteins establishing PPIs with scores ≥ 0.2 are presented (OralInt prediction).
| Endocytosis receptors | Type of receptor | Gene name | UniprotKB AC | PPI score | Fold change hNPCs | |
|---|---|---|---|---|---|---|
| E | M | |||||
| Clathrin-dependent endocytosis | GRPCR | ADRB2 | P07550 | 0.4 | 3.6 | |
| ADRB3 | P13945 | 0.3 | 0.4 | |||
| ADRB1 | P08588 | 0.2 | 0.2 | |||
| CCR5 | P51681 | 0.2 | ||||
| CXCR4 | P61073 | 0.2 | ||||
| LDLR | LDLR | P01130 | 0.2 | 1.2 | ||
| RTK | EGFR | P00533 | 0.3 | |||
| ERBB4 | Q15303 | 0.2 | ||||
| FGFR2 | P21802 | 0.2 | 1.7 | |||
| FGFR3 | P22607 | 0.2 | −1.5 | |||
| FGFR4 | P22455 | 0.2 | ||||
| MET | P08581 | 0.4 | ||||
| PDGFRA | P16234 | 0.3 | ||||
| TFR | TFRC | P02786 | 0.2 | |||
| TGFBR | TGFBR2 | P37173 | 0.3 | 0.3 | ||
| TGFBR3 | Q03167 | 0.3 | ||||
| TGFBR1 | P36897 | 0.2 | ||||
|
| ||||||
| Clathrin-independent endocytosis | Caveolin | CAV2 | P51636 | 0.2 | 0.2 | |
| CAV3 | P56539 | 0.2 | 0.6 | |||
| Others | CD81 | P60033 | 0.3 | 0.4 | −1.2 | |
| CLDN1 | O95832 | 0.3 | 0.3 | 2.5 | ||
| IL2RG | P31785 | 0.3 | ||||
| OCLN | Q16625 | −1.3 | ||||
| TIM | HAVCR2 | Q8TDQ0 | 0.4 | 0.2 | ||
| TAM | AXL | P30530 | 0.2 | 1.3 | ||
| DC-SIGN | CD209 | Q9NNX6 | 0.2 | 0.2 | ||
| L-SIGN | CLEC4M | Q9H2X3 | 0.2 | 0.2 | ||
Human cortical neural progenitor cells (hNPCs) [56].
PPIs established between the different ZIKV proteins and cell receptors and other proteins with an effector or signalling role in the immune response. Only proteins establishing PPIs with scores ≥ 0.2 are presented (OralInt prediction).
| Pathway | Gene Name | UniprotKB AC | OralInt score | Fold change hNPCs | Fold change skin 6 h | Fold change skin 24 h | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | M | NS1 | NS2A | NS2B | NS3 | NS4A | NS4B | NS5 | ||||||
| IFN receptor | IFNAR1 | P17181 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | 0.3 | −1.3 | −1.4 | −1.3 | |||
| IFNAR2 | P48551 | 0.2 | 0.2 | 0.2 | ||||||||||
|
| ||||||||||||||
| Toll-like receptor | TLR2 | O60603 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.4 | 0.3 | |||||
| TLR4 | O00206 | 0.3 | 0.2 | 0.4 | 0.3 | 0.2 | 0.3 | 0.2 | ||||||
| TLR5 | O60602 | |||||||||||||
| TLR6 | Q9Y2C9 | 0.2 | 0.2 | 0.2 | 0.5 | 0.4 | 0.3 | 0.2 | ||||||
|
| ||||||||||||||
| Complement | C2 | P06681 | 0.2 | 0.3 | 0.3 | 0.3 | 0.2 | |||||||
| C3 | P01024 | 0.3 | 0.5 | 0.5 | 0.4 | |||||||||
| C4A | P0C0L4 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | ||||||
| C4B | P0C0L5 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | |||||||
| C5 | P01031 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.2 | 0.2 | |||||
| C6 | P13671 | 0.3 | 0.7 | 0.2 | 0.5 | 0.5 | 0.4 | 0.2 | 0.2 | |||||
| C7 | P10643 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |||||||
| C8A | P07357 | 0.3 | 0.4 | 0.3 | 0.3 | 0.4 | 0.3 | 0.3 | ||||||
| C8B | P07358 | 0.5 | 0.6 | 0.5 | 0.4 | 0.5 | 0.6 | 0.4 | 0.5 | 0.6 | ||||
| C8G | P07360 | 0.3 | 0.4 | 0.2 | 0.3 | 0.5 | 0.3 | 0.3 | 0.5 | 0.3 | ||||
| C9 | P02748 | 0.2 | 0.2 | 0.3 | 0.0 | |||||||||
|
| ||||||||||||||
| Cytokines | IL1B | P01584 | 0.3 | 0.3 | 0.4 | 0.2 | 0.2 | 0.2 | 0.3 | 0.4 | −3.2 | −5.3 | ||
| IL6 | P05231 | 0.4 | 0.3 | 0.4 | 0.2 | 0.3 | 0.2 | 0.4 | 0.4 | 1.1 | 8.2 | |||
| IL17 | Q16552 | 0.4 | 0.6 | 0.4 | 0.2 | 0.5 | 0.3 | 0.4 | 0.6 | 0.4 | ||||
| IL17F | Q96PD4 | 0.2 | 0.2 | 0.2 | ||||||||||
| IL23A | Q9NPF7 | 0.2 | 0.4 | 0.2 | ||||||||||
| IL31 | Q6EBC2 | 0.4 | 0.4 | 0.3 | 0.2 | 0.3 | 0.3 | 0.2 | 0.4 | 0.4 | ||||
| CD40L | P29965 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | |||||||
| IFNG | P01579 | 0.2 | 0.4 | 0.5 | 0.2 | |||||||||
| TNFA | P01375 | 0.2 | −1.7 | −2.1 | ||||||||||
| IL22 | Q9GZX6 | 0.2 | ||||||||||||
| IL21 | Q9HBE4 | 0.3 | 0.3 | 0.3 | 0.3 | |||||||||
| IL33 | O95760 | 0.2 | 0.2 | |||||||||||
| IL4 | P05112 | 0.3 | 0.5 | 0.4 | 0.3 | 0.3 | 0.2 | 0.4 | 0.7 | 0.2 | ||||
| IL10 | P22301 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | ||||
| IL25 | Q9H293 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | ||||||
|
| ||||||||||||||
| Chemokines | CCL2 (MCP-1) | P13500 | ||||||||||||
| CCL3 (MIP-1a) | P10147 | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.2 | 0.2 | 0.2 | −1.7 | −1.4 | |||
| CCL4 (MIP-1 | P13236 | 0.4 | 0.2 | 0.3 | 0.3 | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | ||||
| CXCL1 (Gro-a) | P09341 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.4 | 0.5 | 0.7 | 0.4 | ||||
| CXCL2 (Gro- | P19875 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.4 | 0.5 | 0.7 | 0.4 | ||||
| CXCL3 | P19876 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.4 | 0.5 | 0.7 | 0.4 | ||||
| CXCL8 (IL-8) | P10145 | 0.2 | 0.5 | 0.3 | 0.3 | 0.5 | 0.5 | 0.5 | 0.2 | −2.8 | 3.7 | |||
Human cortical neural progenitor cells (hNPCs) [56]. Skin (fibroblasts) [17].
PPIs established between the nonstructural proteins of ZIKV and proteins of the host pathways leading to an antiviral state. Only proteins establishing PPIs with scores ≥ 0.2 are presented (OralInt prediction).
| Pathway | Gene name | UniprotKB AC | PPI score with NS1 | PPI score with NS2A | PPI score with NS2B | PPI score with NS3 | PPI score with NS4A | PPI score with NS4B | PPI score with NS5 | Fold change hNPCs | Fold change skin 6 h | Fold change skin 24 h |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IFN receptor | IRF9 | Q00978 | 0.2 | 0.2 | ||||||||
| JAK1 | P23458 | 0.2 | 0.3 | 0.4 | 0.3 | 0.4 | 0.3 | 1.3 | ||||
| TYK2 | P29597 | 0.3 | 0.3 | 0.3 | 0.2 | 0.3 | 0.2 | 1.5 | ||||
|
| ||||||||||||
| Toll-like receptor | TNF | P01375 | 0.2 | −1.7 | −2.1 | |||||||
| IRAK1 | P51617 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | −1.3 | 1.4 | 1.6 | |||
| IRAK2 | O43187 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | ||||||
| IRAK4 | Q9NWZ3 | 0.2 | 0.2 | 0.2 | ||||||||
| IKBKG (NEMO) | Q9Y6K9 | 0.3 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | |||||
| MYD88 | Q99836 | 0.4 | 0.4 | 0.2 | 0.2 | 0.3 | 0.2 | −1.8 | −1.0 | 1.8 | ||
| NFKB | P19838 | 0.2 | 0.3 | 0.4 | 0.2 | 0.2 | 0.2 | 0.4 | 1.3 | 1.2 | 1.6 | |
| TLR7 | Q9NYK1 | −1.7 | −1.4 | |||||||||
| TLR8 | Q9NR97 | −1.7 | −1.4 | |||||||||
| TLR9 | Q9NR96 | −1.0 | −2.3 | |||||||||
| TBK1 | Q9UHD2 | 0.2 | 0.2 | 1.6 | −1.2 | 1.1 | ||||||
|
| ||||||||||||
| RIG-like receptor | DDX3X (DDX3) | O00571 | 0.2 | 1.3 | −1.1 | |||||||
| IKBKE (IKK | Q14164 | 0.3 | 0.4 | 0.2 | 0.2 | |||||||
| TRIM25 | Q14258 | 0.4 | 0.6 | 0.4 | 0.3 | 0.4 | 0.4 | 1.4 | 1.8 | |||
| STAT1 | P42224 | 0.8 | 0.5 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 1.1 | 1.8 | ||
| STAT2 | P52630 | 0.3 | 0.3 | 0.2 | 0.3 | 0.2 | ||||||
| DDX58 (RIG-I) | O95786 | 0.2 | 0.2 | 0.2 | 2.0 | −3.2 | 4.9 | |||||
|
| ||||||||||||
| PKR-RNA and stress sensors (apoptosis modulation) | CASP8 | Q14790 | 2.0 | 1.3 | ||||||||
| CASP10 | Q92851 | 0.2 | 3.3 | 3.3 | ||||||||
| FADD | Q13158 | 0.2 | 0.1 | 1.5 | −1.3 | −1.1 | ||||||
| RIPK1 (RIP1) | Q13546 | 0.2 | 0.2 | 0.5 | 0.3 | 0.3 | 0.2 | 1.6 | 1.4 | |||
| TRADD | Q15628 | 1.5 | 1.3 | |||||||||
|
| ||||||||||||
| Mitochondria antiviral immunity | IFNA1 (IFN | P01562 | 0.2 | 0.2 | 2.3 | 3.4 | ||||||
| IFNB1 (IFN | P01574 | 0.3 | 0.2 | 0.3 | 0.2 | 0.3 | 0.4 | −1.7 | 3.7 | |||
|
| ||||||||||||
| Toll/mitochondria antiviral immunity | TRAF6 | Q9Y4K3 | 0.4 | 0.5 | 0.2 | 0.2 | 0.2 | 0.4 | 0.5 | 1.3 | 1.3 | −1.1 |
| IFIH1 (MDA5) | Q9BYX4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.4 | 0.3 | 0.6 | −1.4 | 7.3 | ||
|
| ||||||||||||
| RIG/mitochondria antiviral immunity | IRF3 | Q14653 | 0.3 | 0.2 | 0.2 | −1.1 | −1.1 | |||||
| MAVS | Q7Z434 | −1.3 | −1.0 | −1.5 | ||||||||
|
| ||||||||||||
| Toll/RIG/mitochondria antiviral immunity | CHUK (IKK | O15111 | 0.3 | 0.3 | 0.4 | 0.2 | 0.4 | 0.2 | 0.3 | 1.3 | 1.0 | 1.2 |
| IKBKB (IKK | O14920 | 0.2 | 0.4 | 0.6 | 0.4 | 0.2 | 0.2 | −1.9 | 1.7 | 1.1 | ||
| IRF7 | Q92985 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 1.6 | 1.3 | 3.2 | |||
Human cortical neural progenitor cells (hNPCs) [56]. Skin (fibroblasts) [17].
Figure 2Diagram representing membrane and cytosolic targets of ZIKV used for host cell entry and immune response modulation. Information was obtained from OralInt predicted PPIs and the literature [60–64].
Figure 3Summary diagram of the proposed ZIKV targets considering the intra- and extracellular localization of the viral proteins during the infection cycle. Scores of the OralInt predicted PPIs are presented next to each human protein target and refer to interaction with the specific ZIKV protein. The proposed membrane orientation of the ZIKV proteins was modified from Figure 25.4 in Shi and Gao (2017) [54].